Integrin αvβ3 a potential prognostic biomarker OF chemotherapy response in breast cancer

DIAZ ALBUJA J.A.; STERLE H.A.; CAYROL F.; PAULAZO M.A.; CAMPOS HAEDO M.; DEBERNARDI M.; ROSEMBLIT C.; CREMASCHI G.A.; DÍAZ FLAQUÉ M.C.

Ciudad Autónoma de Buenos Aires

Congreso; SAFIS + ALACF joint meeting 2021; 2021

SAFIS y ALACF

Despite the development of novel therapies, breast cancer (BC) tumors are treated with conventional therapy sooner or later. Due to tumor heterogeneity, it is necessary to define new biomarkers to identify groups with different molecular characteristic to improve the correct treatment decision. The impact of thyroid status in BC growth has previously been studied. It has been found alterations of thyroid function during chemotherapy BC treatment and demonstrated that T3 induces chemosensitization of BC cells. However, the relationship between thyroid hormones (THs) membrane receptor, integrin αvβ3 and BC response to chemotherapy remains unclear. The aim of this study is to evaluate the relationship between THs and integrin αvβ3 expression as prognostic value in BC patients. The mRNA expression of ITGB3 in TCGA-PanCancer Atlas, BC dataset (1084 patients) were correlated with ABCB1 and ABCG2, (Pearson, R score >0.3 and p